Pharma & Healthcare
Global Meningococcal Vaccine Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2025-2031
- Jun 01, 25
- ID: 285459
- Pages: 143
- Figures: 143
- Views: 18
In 2024, the global market size of Meningococcal Vaccine was estimated to be worth US$ 285 million and is forecast to reach approximately US$ 384 million by 2031 with a CAGR of 4.4% during the forecast period 2025-2031.
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.
Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.
In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Meningococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Vaccine.
The Meningococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (10K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Meningococcal Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meningococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.
By Company
Novartis
GSK
Merck
CSL
Baxter
JN International Medical Corporation
Serum Institute of India
Bio-Med
China National Biotec Group
Hualan Bio
Walvax
Zhifei
Segment by Type
Meningtits A
Polysaccharide Meningtitis AC
Meningitis ACYW
Segment by Application
6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Meningococcal Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Vaccine sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
Meningococcal vaccine refers to any of the vaccines used to prevent infection by Neisseria meningitides. The vaccines are between 85 and 100% effective for at least two years. They result in a decrease in meningitis and sepsis among populations where they are widely used. They are given either by injection into a muscle or just under the skin.
Global Meningococcal Vaccine key players include GSK, SANOFI PASTEUR S.A, Norvatis, Crucell, Medimmune, etc. Global top five players hold a share about 80%.
Europe is the largest market, with a share about 45%, followed by North America and China, having a total share about 40 percent.
In terms of product, Polysaccharide Meningtitis AC is the largest segment, with a share about 95%. And in terms of application, the largest application is 6 Months-15Year, followed by over 3 Year, over 2 Year, over 3 Months.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Meningococcal Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Meningococcal Vaccine.
The Meningococcal Vaccine market size, estimations, and forecasts are provided in terms of sales volume (10K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Meningococcal Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Meningococcal Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.
By Company
Novartis
GSK
Merck
CSL
Baxter
JN International Medical Corporation
Serum Institute of India
Bio-Med
China National Biotec Group
Hualan Bio
Walvax
Zhifei
Segment by Type
Meningtits A
Polysaccharide Meningtitis AC
Meningitis ACYW
Segment by Application
6 Months-15Year
over 3 Year
over 2 Year
over 3 Months
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Meningococcal Vaccine in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Meningococcal Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Vaccine sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
1 Study Coverage
1.1 Meningococcal Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Meningococcal Vaccine Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Meningtits A
1.2.3 Polysaccharide Meningtitis AC
1.2.4 Meningitis ACYW
1.3 Market by Application
1.3.1 Global Meningococcal Vaccine Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 6 Months-15Year
1.3.3 over 3 Year
1.3.4 over 2 Year
1.3.5 over 3 Months
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Meningococcal Vaccine Market Size Estimates and Forecasts
2.1.1 Global Meningococcal Vaccine Revenue 2020-2031
2.1.2 Global Meningococcal Vaccine Sales 2020-2031
2.2 Meningococcal Vaccine Market Size by Region: 2024 Versus 2031
2.3 Meningococcal Vaccine Sales by Region (2020-2031)
2.3.1 Global Meningococcal Vaccine Sales by Region: 2020-2025
2.3.2 Global Meningococcal Vaccine Sales Forecast by Region (2026-2031)
2.3.3 Global Meningococcal Vaccine Sales Market Share by Region (2020-2031)
2.4 Meningococcal Vaccine Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Meningococcal Vaccine Revenue by Region: 2020-2025
2.4.2 Global Meningococcal Vaccine Revenue Forecast by Region (2026-2031)
2.4.3 Global Meningococcal Vaccine Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Meningococcal Vaccine Sales by Type (2020-2031)
3.1.1.1 Global Meningococcal Vaccine Sales Volume by Type (2020-2031)
3.1.1.2 Global Meningococcal Vaccine Sales Market Share by Type (2020-2031)
3.1.2 Global Meningococcal Vaccine Revenue by Type (2020-2031)
3.1.2.1 Global Meningococcal Vaccine Revenue by Type (2020-2031)
3.1.2.2 Global Meningococcal Vaccine Revenue Market Share by Type (2020-2031)
3.1.3 Meningococcal Vaccine Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Meningococcal Vaccine Sales by Application (2020-2031)
3.2.1.1 Global Meningococcal Vaccine Sales Volume by Application (2020-2031)
3.2.1.2 Global Meningococcal Vaccine Sales Market Share by Application (2020-2031)
3.2.2 Global Meningococcal Vaccine Revenue by Application (2020-2031)
3.2.2.1 Global Meningococcal Vaccine Revenue by Application (2020-2031)
3.2.2.2 Global Meningococcal Vaccine Revenue Market Share by Application (2020-2031)
3.2.3 Meningococcal Vaccine Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Meningtits A of Meningococcal Vaccine Revenue Market Share by Application
3.3.2 Polysaccharide Meningtitis AC of Meningococcal Vaccine Revenue Market Share by Application
3.3.3 Meningitis ACYW of Meningococcal Vaccine Revenue Market Share by Application
4 Global Meningococcal Vaccine by Manufacturers
4.1 Global Top Meningococcal Vaccine Manufacturers by Sales (2020-2025)
4.1.1 Global Meningococcal Vaccine Sales by Manufacturer (2020-2025)
4.1.2 Global Meningococcal Vaccine Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Meningococcal Vaccine Manufacturers by Revenue (2020-2025)
4.2.1 Global Meningococcal Vaccine Revenue by Manufacturer (2020-2025)
4.2.2 Global Meningococcal Vaccine Revenue Share by Manufacturer (2020-2025)
4.3 Global Meningococcal Vaccine Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Meningococcal Vaccine Manufacturers Covered: Ranking by Revenue
4.4.2 Global Meningococcal Vaccine Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Meningococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Meningococcal Vaccine Manufacturing Base Distribution, Product Type
4.5.1 Meningococcal Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Meningococcal Vaccine Market
4.5.3 Manufacturers Meningococcal Vaccine Product Type and Application
4.5.4 Meningtits A Market Sales of Meningococcal Vaccine by Manufacturer
4.5.5 Polysaccharide Meningtitis AC Market Sales of Meningococcal Vaccine by Manufacturer
4.5.6 Meningitis ACYW Market Sales of Meningococcal Vaccine by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Novartis
5.1.1 Novartis Company Information
5.1.2 Novartis Description, Business Overview
5.1.3 Novartis Meningococcal Vaccine Products Offered
5.1.4 Novartis Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Novartis Meningococcal Vaccine Sales by Product in 2024
5.1.6 Novartis Meningococcal Vaccine Sales by Application in 2024
5.1.7 Novartis Meningococcal Vaccine Sales by Geographic Area in 2024
5.1.8 Novartis Recent Developments
5.2 GSK
5.2.1 GSK Company Information
5.2.2 GSK Description, Business Overview
5.2.3 GSK Meningococcal Vaccine Products Offered
5.2.4 GSK Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.2.5 GSK Meningococcal Vaccine Sales by Product in 2024
5.2.6 GSK Meningococcal Vaccine Sales by Application in 2024
5.2.7 GSK Meningococcal Vaccine Sales by Geographic Area in 2024
5.2.8 GSK Recent Developments
5.3 Merck
5.3.1 Merck Company Information
5.3.2 Merck Description, Business Overview
5.3.3 Merck Meningococcal Vaccine Products Offered
5.3.4 Merck Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.3.5 Merck Meningococcal Vaccine Sales by Product in 2024
5.3.6 Merck Meningococcal Vaccine Sales by Application in 2024
5.3.7 Merck Meningococcal Vaccine Sales by Geographic Area in 2024
5.3.8 Merck Recent Developments
5.4 CSL
5.4.1 CSL Company Information
5.4.2 CSL Description, Business Overview
5.4.3 CSL Meningococcal Vaccine Products Offered
5.4.4 CSL Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.4.5 CSL Meningococcal Vaccine Sales by Product in 2024
5.4.6 CSL Meningococcal Vaccine Sales by Application in 2024
5.4.7 CSL Meningococcal Vaccine Sales by Geographic Area in 2024
5.4.8 CSL Recent Developments
5.5 Baxter
5.5.1 Baxter Company Information
5.5.2 Baxter Description, Business Overview
5.5.3 Baxter Meningococcal Vaccine Products Offered
5.5.4 Baxter Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.5.5 Baxter Meningococcal Vaccine Sales by Product in 2024
5.5.6 Baxter Meningococcal Vaccine Sales by Application in 2024
5.5.7 Baxter Meningococcal Vaccine Sales by Geographic Area in 2024
5.5.8 Baxter Recent Developments
5.6 JN International Medical Corporation
5.6.1 JN International Medical Corporation Company Information
5.6.2 JN International Medical Corporation Description, Business Overview
5.6.3 JN International Medical Corporation Meningococcal Vaccine Products Offered
5.6.4 JN International Medical Corporation Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.6.5 JN International Medical Corporation Meningococcal Vaccine Sales by Product in 2024
5.6.6 JN International Medical Corporation Meningococcal Vaccine Sales by Application in 2024
5.6.7 JN International Medical Corporation Meningococcal Vaccine Sales by Geographic Area in 2024
5.6.8 JN International Medical Corporation Recent Developments
5.7 Serum Institute of India
5.7.1 Serum Institute of India Company Information
5.7.2 Serum Institute of India Description, Business Overview
5.7.3 Serum Institute of India Meningococcal Vaccine Products Offered
5.7.4 Serum Institute of India Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.7.5 Serum Institute of India Meningococcal Vaccine Sales by Product in 2024
5.7.6 Serum Institute of India Meningococcal Vaccine Sales by Application in 2024
5.7.7 Serum Institute of India Meningococcal Vaccine Sales by Geographic Area in 2024
5.7.8 Serum Institute of India Recent Developments
5.8 Bio-Med
5.8.1 Bio-Med Company Information
5.8.2 Bio-Med Description, Business Overview
5.8.3 Bio-Med Meningococcal Vaccine Products Offered
5.8.4 Bio-Med Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.8.5 Bio-Med Meningococcal Vaccine Sales by Product in 2024
5.8.6 Bio-Med Meningococcal Vaccine Sales by Application in 2024
5.8.7 Bio-Med Meningococcal Vaccine Sales by Geographic Area in 2024
5.8.8 Bio-Med Recent Developments
5.9 China National Biotec Group
5.9.1 China National Biotec Group Company Information
5.9.2 China National Biotec Group Description, Business Overview
5.9.3 China National Biotec Group Meningococcal Vaccine Products Offered
5.9.4 China National Biotec Group Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.9.5 China National Biotec Group Meningococcal Vaccine Sales by Product in 2024
5.9.6 China National Biotec Group Meningococcal Vaccine Sales by Application in 2024
5.9.7 China National Biotec Group Meningococcal Vaccine Sales by Geographic Area in 2024
5.9.8 China National Biotec Group Recent Developments
5.10 Hualan Bio
5.10.1 Hualan Bio Company Information
5.10.2 Hualan Bio Description, Business Overview
5.10.3 Hualan Bio Meningococcal Vaccine Products Offered
5.10.4 Hualan Bio Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.10.5 Hualan Bio Meningococcal Vaccine Sales by Product in 2024
5.10.6 Hualan Bio Meningococcal Vaccine Sales by Application in 2024
5.10.7 Hualan Bio Meningococcal Vaccine Sales by Geographic Area in 2024
5.10.8 Hualan Bio Recent Developments
5.11 Walvax
5.11.1 Walvax Company Information
5.11.2 Walvax Description, Business Overview
5.11.3 Walvax Meningococcal Vaccine Products Offered
5.11.4 Walvax Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.11.5 Walvax Meningococcal Vaccine Sales by Product in 2024
5.11.6 Walvax Meningococcal Vaccine Sales by Application in 2024
5.11.7 Walvax Meningococcal Vaccine Sales by Geographic Area in 2024
5.11.8 Walvax Recent Developments
5.12 Zhifei
5.12.1 Zhifei Company Information
5.12.2 Zhifei Description, Business Overview
5.12.3 Zhifei Meningococcal Vaccine Products Offered
5.12.4 Zhifei Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.12.5 Zhifei Meningococcal Vaccine Sales by Product in 2024
5.12.6 Zhifei Meningococcal Vaccine Sales by Application in 2024
5.12.7 Zhifei Meningococcal Vaccine Sales by Geographic Area in 2024
5.12.8 Zhifei Recent Developments
6 North America
6.1 North America Meningococcal Vaccine Market Size YoY Growth 2020-2031
6.2 North America Meningococcal Vaccine Market Facts & Figures by Country
6.2.1 North America Meningococcal Vaccine Sales by Country (2020-2031)
6.2.2 North America Meningococcal Vaccine Revenue by Country (2020-2031)
6.3 North America Meningococcal Vaccine Sales by Type (2020-2025)
6.4 North America Meningococcal Vaccine Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Meningococcal Vaccine Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Meningococcal Vaccine Market Facts & Figures by Region
7.2.1 Asia-Pacific Meningococcal Vaccine Sales by Region (2020-2031)
7.2.2 Asia-Pacific Meningococcal Vaccine Revenue by Region (2020-2031)
7.3 Asia-Pacific Meningococcal Vaccine Sales by Type (2020-2025)
7.4 Asia-Pacific Meningococcal Vaccine Sales by Application (2020-2025)
8 Europe
8.1 Europe Meningococcal Vaccine Market Size YoY Growth 2020-2031
8.2 Europe Meningococcal Vaccine Market Facts & Figures by Country
8.2.1 Europe Meningococcal Vaccine Sales by Country (2020-2031)
8.2.2 Europe Meningococcal Vaccine Revenue by Country (2020-2031)
8.3 Europe Meningococcal Vaccine Sales by Type (2020-2025)
8.4 Europe Meningococcal Vaccine Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Meningococcal Vaccine Market Size YoY Growth 2020-2031
9.2 Latin America Meningococcal Vaccine Market Facts & Figures by Country
9.2.1 Latin America Meningococcal Vaccine Sales by Country (2020-2031)
9.2.2 Latin America Meningococcal Vaccine Revenue by Country (2020-2031)
9.3 Latin America Meningococcal Vaccine Sales by Type (2020-2025)
9.4 Latin America Meningococcal Vaccine Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Meningococcal Vaccine Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Meningococcal Vaccine Market Facts & Figures by Country
10.2.1 Middle East and Africa Meningococcal Vaccine Sales by Country (2020-2031)
10.2.2 Middle East and Africa Meningococcal Vaccine Revenue by Country (2020-2031)
10.3 Middle East and Africa Meningococcal Vaccine Sales by Type (2020-2025)
10.4 Middle East and Africa Meningococcal Vaccine Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Meningococcal Vaccine Supply Chain Analysis
11.2 Meningococcal Vaccine Key Raw Materials and Upstream Suppliers
11.3 Meningococcal Vaccine Clients Analysis
11.4 Meningococcal Vaccine Sales Channel and Sales Model Analysis
11.4.1 Meningococcal Vaccine Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Meningococcal Vaccine Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Meningococcal Vaccine Distributors
12 Meningococcal Vaccine Market Dynamics
12.1 Meningococcal Vaccine Industry Trends
12.2 Meningococcal Vaccine Market Drivers
12.3 Meningococcal Vaccine Market Challenges
12.4 Meningococcal Vaccine Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
1.1 Meningococcal Vaccine Product Introduction
1.2 Market by Type
1.2.1 Global Meningococcal Vaccine Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Meningtits A
1.2.3 Polysaccharide Meningtitis AC
1.2.4 Meningitis ACYW
1.3 Market by Application
1.3.1 Global Meningococcal Vaccine Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 6 Months-15Year
1.3.3 over 3 Year
1.3.4 over 2 Year
1.3.5 over 3 Months
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Meningococcal Vaccine Market Size Estimates and Forecasts
2.1.1 Global Meningococcal Vaccine Revenue 2020-2031
2.1.2 Global Meningococcal Vaccine Sales 2020-2031
2.2 Meningococcal Vaccine Market Size by Region: 2024 Versus 2031
2.3 Meningococcal Vaccine Sales by Region (2020-2031)
2.3.1 Global Meningococcal Vaccine Sales by Region: 2020-2025
2.3.2 Global Meningococcal Vaccine Sales Forecast by Region (2026-2031)
2.3.3 Global Meningococcal Vaccine Sales Market Share by Region (2020-2031)
2.4 Meningococcal Vaccine Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Meningococcal Vaccine Revenue by Region: 2020-2025
2.4.2 Global Meningococcal Vaccine Revenue Forecast by Region (2026-2031)
2.4.3 Global Meningococcal Vaccine Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Meningococcal Vaccine Sales by Type (2020-2031)
3.1.1.1 Global Meningococcal Vaccine Sales Volume by Type (2020-2031)
3.1.1.2 Global Meningococcal Vaccine Sales Market Share by Type (2020-2031)
3.1.2 Global Meningococcal Vaccine Revenue by Type (2020-2031)
3.1.2.1 Global Meningococcal Vaccine Revenue by Type (2020-2031)
3.1.2.2 Global Meningococcal Vaccine Revenue Market Share by Type (2020-2031)
3.1.3 Meningococcal Vaccine Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Meningococcal Vaccine Sales by Application (2020-2031)
3.2.1.1 Global Meningococcal Vaccine Sales Volume by Application (2020-2031)
3.2.1.2 Global Meningococcal Vaccine Sales Market Share by Application (2020-2031)
3.2.2 Global Meningococcal Vaccine Revenue by Application (2020-2031)
3.2.2.1 Global Meningococcal Vaccine Revenue by Application (2020-2031)
3.2.2.2 Global Meningococcal Vaccine Revenue Market Share by Application (2020-2031)
3.2.3 Meningococcal Vaccine Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Meningtits A of Meningococcal Vaccine Revenue Market Share by Application
3.3.2 Polysaccharide Meningtitis AC of Meningococcal Vaccine Revenue Market Share by Application
3.3.3 Meningitis ACYW of Meningococcal Vaccine Revenue Market Share by Application
4 Global Meningococcal Vaccine by Manufacturers
4.1 Global Top Meningococcal Vaccine Manufacturers by Sales (2020-2025)
4.1.1 Global Meningococcal Vaccine Sales by Manufacturer (2020-2025)
4.1.2 Global Meningococcal Vaccine Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Meningococcal Vaccine Manufacturers by Revenue (2020-2025)
4.2.1 Global Meningococcal Vaccine Revenue by Manufacturer (2020-2025)
4.2.2 Global Meningococcal Vaccine Revenue Share by Manufacturer (2020-2025)
4.3 Global Meningococcal Vaccine Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Meningococcal Vaccine Manufacturers Covered: Ranking by Revenue
4.4.2 Global Meningococcal Vaccine Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Meningococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Meningococcal Vaccine Manufacturing Base Distribution, Product Type
4.5.1 Meningococcal Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Meningococcal Vaccine Market
4.5.3 Manufacturers Meningococcal Vaccine Product Type and Application
4.5.4 Meningtits A Market Sales of Meningococcal Vaccine by Manufacturer
4.5.5 Polysaccharide Meningtitis AC Market Sales of Meningococcal Vaccine by Manufacturer
4.5.6 Meningitis ACYW Market Sales of Meningococcal Vaccine by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Novartis
5.1.1 Novartis Company Information
5.1.2 Novartis Description, Business Overview
5.1.3 Novartis Meningococcal Vaccine Products Offered
5.1.4 Novartis Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Novartis Meningococcal Vaccine Sales by Product in 2024
5.1.6 Novartis Meningococcal Vaccine Sales by Application in 2024
5.1.7 Novartis Meningococcal Vaccine Sales by Geographic Area in 2024
5.1.8 Novartis Recent Developments
5.2 GSK
5.2.1 GSK Company Information
5.2.2 GSK Description, Business Overview
5.2.3 GSK Meningococcal Vaccine Products Offered
5.2.4 GSK Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.2.5 GSK Meningococcal Vaccine Sales by Product in 2024
5.2.6 GSK Meningococcal Vaccine Sales by Application in 2024
5.2.7 GSK Meningococcal Vaccine Sales by Geographic Area in 2024
5.2.8 GSK Recent Developments
5.3 Merck
5.3.1 Merck Company Information
5.3.2 Merck Description, Business Overview
5.3.3 Merck Meningococcal Vaccine Products Offered
5.3.4 Merck Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.3.5 Merck Meningococcal Vaccine Sales by Product in 2024
5.3.6 Merck Meningococcal Vaccine Sales by Application in 2024
5.3.7 Merck Meningococcal Vaccine Sales by Geographic Area in 2024
5.3.8 Merck Recent Developments
5.4 CSL
5.4.1 CSL Company Information
5.4.2 CSL Description, Business Overview
5.4.3 CSL Meningococcal Vaccine Products Offered
5.4.4 CSL Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.4.5 CSL Meningococcal Vaccine Sales by Product in 2024
5.4.6 CSL Meningococcal Vaccine Sales by Application in 2024
5.4.7 CSL Meningococcal Vaccine Sales by Geographic Area in 2024
5.4.8 CSL Recent Developments
5.5 Baxter
5.5.1 Baxter Company Information
5.5.2 Baxter Description, Business Overview
5.5.3 Baxter Meningococcal Vaccine Products Offered
5.5.4 Baxter Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.5.5 Baxter Meningococcal Vaccine Sales by Product in 2024
5.5.6 Baxter Meningococcal Vaccine Sales by Application in 2024
5.5.7 Baxter Meningococcal Vaccine Sales by Geographic Area in 2024
5.5.8 Baxter Recent Developments
5.6 JN International Medical Corporation
5.6.1 JN International Medical Corporation Company Information
5.6.2 JN International Medical Corporation Description, Business Overview
5.6.3 JN International Medical Corporation Meningococcal Vaccine Products Offered
5.6.4 JN International Medical Corporation Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.6.5 JN International Medical Corporation Meningococcal Vaccine Sales by Product in 2024
5.6.6 JN International Medical Corporation Meningococcal Vaccine Sales by Application in 2024
5.6.7 JN International Medical Corporation Meningococcal Vaccine Sales by Geographic Area in 2024
5.6.8 JN International Medical Corporation Recent Developments
5.7 Serum Institute of India
5.7.1 Serum Institute of India Company Information
5.7.2 Serum Institute of India Description, Business Overview
5.7.3 Serum Institute of India Meningococcal Vaccine Products Offered
5.7.4 Serum Institute of India Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.7.5 Serum Institute of India Meningococcal Vaccine Sales by Product in 2024
5.7.6 Serum Institute of India Meningococcal Vaccine Sales by Application in 2024
5.7.7 Serum Institute of India Meningococcal Vaccine Sales by Geographic Area in 2024
5.7.8 Serum Institute of India Recent Developments
5.8 Bio-Med
5.8.1 Bio-Med Company Information
5.8.2 Bio-Med Description, Business Overview
5.8.3 Bio-Med Meningococcal Vaccine Products Offered
5.8.4 Bio-Med Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.8.5 Bio-Med Meningococcal Vaccine Sales by Product in 2024
5.8.6 Bio-Med Meningococcal Vaccine Sales by Application in 2024
5.8.7 Bio-Med Meningococcal Vaccine Sales by Geographic Area in 2024
5.8.8 Bio-Med Recent Developments
5.9 China National Biotec Group
5.9.1 China National Biotec Group Company Information
5.9.2 China National Biotec Group Description, Business Overview
5.9.3 China National Biotec Group Meningococcal Vaccine Products Offered
5.9.4 China National Biotec Group Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.9.5 China National Biotec Group Meningococcal Vaccine Sales by Product in 2024
5.9.6 China National Biotec Group Meningococcal Vaccine Sales by Application in 2024
5.9.7 China National Biotec Group Meningococcal Vaccine Sales by Geographic Area in 2024
5.9.8 China National Biotec Group Recent Developments
5.10 Hualan Bio
5.10.1 Hualan Bio Company Information
5.10.2 Hualan Bio Description, Business Overview
5.10.3 Hualan Bio Meningococcal Vaccine Products Offered
5.10.4 Hualan Bio Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.10.5 Hualan Bio Meningococcal Vaccine Sales by Product in 2024
5.10.6 Hualan Bio Meningococcal Vaccine Sales by Application in 2024
5.10.7 Hualan Bio Meningococcal Vaccine Sales by Geographic Area in 2024
5.10.8 Hualan Bio Recent Developments
5.11 Walvax
5.11.1 Walvax Company Information
5.11.2 Walvax Description, Business Overview
5.11.3 Walvax Meningococcal Vaccine Products Offered
5.11.4 Walvax Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.11.5 Walvax Meningococcal Vaccine Sales by Product in 2024
5.11.6 Walvax Meningococcal Vaccine Sales by Application in 2024
5.11.7 Walvax Meningococcal Vaccine Sales by Geographic Area in 2024
5.11.8 Walvax Recent Developments
5.12 Zhifei
5.12.1 Zhifei Company Information
5.12.2 Zhifei Description, Business Overview
5.12.3 Zhifei Meningococcal Vaccine Products Offered
5.12.4 Zhifei Meningococcal Vaccine Sales, Revenue and Gross Margin (2020-2025)
5.12.5 Zhifei Meningococcal Vaccine Sales by Product in 2024
5.12.6 Zhifei Meningococcal Vaccine Sales by Application in 2024
5.12.7 Zhifei Meningococcal Vaccine Sales by Geographic Area in 2024
5.12.8 Zhifei Recent Developments
6 North America
6.1 North America Meningococcal Vaccine Market Size YoY Growth 2020-2031
6.2 North America Meningococcal Vaccine Market Facts & Figures by Country
6.2.1 North America Meningococcal Vaccine Sales by Country (2020-2031)
6.2.2 North America Meningococcal Vaccine Revenue by Country (2020-2031)
6.3 North America Meningococcal Vaccine Sales by Type (2020-2025)
6.4 North America Meningococcal Vaccine Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Meningococcal Vaccine Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Meningococcal Vaccine Market Facts & Figures by Region
7.2.1 Asia-Pacific Meningococcal Vaccine Sales by Region (2020-2031)
7.2.2 Asia-Pacific Meningococcal Vaccine Revenue by Region (2020-2031)
7.3 Asia-Pacific Meningococcal Vaccine Sales by Type (2020-2025)
7.4 Asia-Pacific Meningococcal Vaccine Sales by Application (2020-2025)
8 Europe
8.1 Europe Meningococcal Vaccine Market Size YoY Growth 2020-2031
8.2 Europe Meningococcal Vaccine Market Facts & Figures by Country
8.2.1 Europe Meningococcal Vaccine Sales by Country (2020-2031)
8.2.2 Europe Meningococcal Vaccine Revenue by Country (2020-2031)
8.3 Europe Meningococcal Vaccine Sales by Type (2020-2025)
8.4 Europe Meningococcal Vaccine Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Meningococcal Vaccine Market Size YoY Growth 2020-2031
9.2 Latin America Meningococcal Vaccine Market Facts & Figures by Country
9.2.1 Latin America Meningococcal Vaccine Sales by Country (2020-2031)
9.2.2 Latin America Meningococcal Vaccine Revenue by Country (2020-2031)
9.3 Latin America Meningococcal Vaccine Sales by Type (2020-2025)
9.4 Latin America Meningococcal Vaccine Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Meningococcal Vaccine Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Meningococcal Vaccine Market Facts & Figures by Country
10.2.1 Middle East and Africa Meningococcal Vaccine Sales by Country (2020-2031)
10.2.2 Middle East and Africa Meningococcal Vaccine Revenue by Country (2020-2031)
10.3 Middle East and Africa Meningococcal Vaccine Sales by Type (2020-2025)
10.4 Middle East and Africa Meningococcal Vaccine Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Meningococcal Vaccine Supply Chain Analysis
11.2 Meningococcal Vaccine Key Raw Materials and Upstream Suppliers
11.3 Meningococcal Vaccine Clients Analysis
11.4 Meningococcal Vaccine Sales Channel and Sales Model Analysis
11.4.1 Meningococcal Vaccine Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Meningococcal Vaccine Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Meningococcal Vaccine Distributors
12 Meningococcal Vaccine Market Dynamics
12.1 Meningococcal Vaccine Industry Trends
12.2 Meningococcal Vaccine Market Drivers
12.3 Meningococcal Vaccine Market Challenges
12.4 Meningococcal Vaccine Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Meningococcal Vaccine Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Meningococcal Vaccine Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Meningococcal Vaccine Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Meningococcal Vaccine Sales by Region (2020-2025) & (10K Pcs)
Table 5. Global Meningococcal Vaccine Sales Forecast by Region (2026-2031) & (10K Pcs)
Table 6. Global Meningococcal Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 7. Global Meningococcal Vaccine Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 8. Global Meningococcal Vaccine Sales Volume by Type (2020-2025) & (10K Pcs)
Table 9. Global Meningococcal Vaccine Sales Volume by Type (2026-2031) & (10K Pcs)
Table 10. Global Meningococcal Vaccine Revenue by Type (2020-2025) & (US$ Million)
Table 11. Global Meningococcal Vaccine Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 12. Global Meningococcal Vaccine Sales Volume by Application (2020-2025) & (10K Pcs)
Table 13. Global Meningococcal Vaccine Sales Volume by Application (2026-2031) & (10K Pcs)
Table 14. Global Meningococcal Vaccine Revenue by Application (2020-2025) & (US$ Million)
Table 15. Global Meningococcal Vaccine Revenue by Application (2026-2031) & (US$ Million)
Table 16. Global Meningococcal Vaccine Sales by Manufacturer (2020-2025) & (10K Pcs)
Table 17. Global Meningococcal Vaccine Sales Share by Manufacturer (2020-2025)
Table 18. Meningococcal Vaccine Revenue by Manufacturer (2020-2025) & (US$ Million)
Table 19. Meningococcal Vaccine Revenue Share by Manufacturer (2020-2025)
Table 20. Key Manufacturers Meningococcal Vaccine Price (2020-2025) & (USD/Pcs)
Table 21. Ranking of Global Top Meningococcal Vaccine Manufacturers by Revenue (US$ Million) in 2024
Table 22. Global Meningococcal Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 23. Global Meningococcal Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Meningococcal Vaccine as of 2024)
Table 24. Meningococcal Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Date of International Manufacturers Enter into Meningococcal Vaccine Market
Table 26. Manufacturers Meningococcal Vaccine Product Type and Application
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Novartis Company Information
Table 29. Novartis Description and Business Overview
Table 30. Novartis Meningococcal Vaccine Product
Table 31. Novartis Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 32. Novartis Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 33. Novartis Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 34. Novartis Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 35. Novartis Recent Developments
Table 36. GSK Company Information
Table 37. GSK Description and Business Overview
Table 38. GSK Meningococcal Vaccine Product
Table 39. GSK Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 40. GSK Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 41. GSK Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 42. GSK Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 43. GSK Recent Developments
Table 44. Merck Company Information
Table 45. Merck Description and Business Overview
Table 46. Merck Meningococcal Vaccine Product
Table 47. Merck Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 48. Merck Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 49. Merck Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 50. Merck Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 51. Merck Recent Developments
Table 52. CSL Company Information
Table 53. CSL Description and Business Overview
Table 54. CSL Meningococcal Vaccine Product
Table 55. CSL Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 56. CSL Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 57. CSL Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 58. CSL Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 59. CSL Recent Developments
Table 60. Baxter Company Information
Table 61. Baxter Description and Business Overview
Table 62. Baxter Meningococcal Vaccine Product
Table 63. Baxter Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 64. Baxter Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 65. Baxter Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 66. Baxter Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 67. Baxter Recent Developments
Table 68. JN International Medical Corporation Company Information
Table 69. JN International Medical Corporation Description and Business Overview
Table 70. JN International Medical Corporation Meningococcal Vaccine Product
Table 71. JN International Medical Corporation Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 72. JN International Medical Corporation Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 73. JN International Medical Corporation Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 74. JN International Medical Corporation Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 75. JN International Medical Corporation Recent Developments
Table 76. Serum Institute of India Company Information
Table 77. Serum Institute of India Description and Business Overview
Table 78. Serum Institute of India Meningococcal Vaccine Product
Table 79. Serum Institute of India Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 80. Serum Institute of India Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 81. Serum Institute of India Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 82. Serum Institute of India Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 83. Serum Institute of India Recent Developments
Table 84. Bio-Med Company Information
Table 85. Bio-Med Description and Business Overview
Table 86. Bio-Med Meningococcal Vaccine Product
Table 87. Bio-Med Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. Bio-Med Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 89. Bio-Med Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 90. Bio-Med Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 91. Bio-Med Recent Developments
Table 92. China National Biotec Group Company Information
Table 93. China National Biotec Group Description and Business Overview
Table 94. China National Biotec Group Meningococcal Vaccine Product
Table 95. China National Biotec Group Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 96. China National Biotec Group Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 97. China National Biotec Group Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 98. China National Biotec Group Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 99. China National Biotec Group Recent Developments
Table 100. Hualan Bio Company Information
Table 101. Hualan Bio Description and Business Overview
Table 102. Hualan Bio Meningococcal Vaccine Product
Table 103. Hualan Bio Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 104. Hualan Bio Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 105. Hualan Bio Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 106. Hualan Bio Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 107. Hualan Bio Recent Developments
Table 108. Walvax Company Information
Table 109. Walvax Description and Business Overview
Table 110. Walvax Meningococcal Vaccine Product
Table 111. Walvax Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 112. Walvax Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 113. Walvax Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 114. Walvax Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 115. Walvax Recent Developments
Table 116. Zhifei Company Information
Table 117. Zhifei Description and Business Overview
Table 118. Zhifei Meningococcal Vaccine Product
Table 119. Zhifei Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 120. Zhifei Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 121. Zhifei Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 122. Zhifei Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 123. Zhifei Recent Developments
Table 124. North America Meningococcal Vaccine Sales by Country (2020-2025) & (10K Pcs)
Table 125. North America Meningococcal Vaccine Sales by Country (2026-2031) & (10K Pcs)
Table 126. North America Meningococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 127. North America Meningococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 128. North America Meningococcal Vaccine Sales by Type (2020-2025) & (10K Pcs)
Table 129. North America Meningococcal Vaccine Sales by Application (2020-2025) & (10K Pcs)
Table 130. Asia-Pacific Meningococcal Vaccine Sales by Region (2020-2025) & (10K Pcs)
Table 131. Asia-Pacific Meningococcal Vaccine Sales by Region (2026-2031) & (10K Pcs)
Table 132. Asia-Pacific Meningococcal Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 133. Asia-Pacific Meningococcal Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 134. Asia-Pacific Meningococcal Vaccine Sales by Type (2020-2025) & (10K Pcs)
Table 135. Asia-Pacific Meningococcal Vaccine Sales by Application (2020-2025) & (10K Pcs)
Table 136. Europe Meningococcal Vaccine Sales by Country (2020-2025) & (10K Pcs)
Table 137. Europe Meningococcal Vaccine Sales by Country (2026-2031) & (10K Pcs)
Table 138. Europe Meningococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 139. Europe Meningococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 140. Europe Meningococcal Vaccine Sales by Type (2020-2025) & (10K Pcs)
Table 141. Europe Meningococcal Vaccine Sales by Application (2020-2025) & (10K Pcs)
Table 142. Latin America Meningococcal Vaccine Sales by Country (2020-2025) & (10K Pcs)
Table 143. Latin America Meningococcal Vaccine Sales by Country (2026-2031) & (10K Pcs)
Table 144. Latin America Meningococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 145. Latin America Meningococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 146. Latin America Meningococcal Vaccine Sales by Type (2020-2025) & (10K Pcs)
Table 147. Latin America Meningococcal Vaccine Sales by Application (2020-2025) & (10K Pcs)
Table 148. Middle East and Africa Meningococcal Vaccine Sales by Country (2020-2025) & (10K Pcs)
Table 149. Middle East and Africa Meningococcal Vaccine Sales by Country (2026-2031) & (10K Pcs)
Table 150. Middle East and Africa Meningococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 151. Middle East and Africa Meningococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 152. Middle East and Africa Meningococcal Vaccine Sales by Type (2020-2025) & (10K Pcs)
Table 153. Middle East and Africa Meningococcal Vaccine Sales by Application (2020-2025) & (10K Pcs)
Table 154. Meningococcal Vaccine Key Raw Materials, Industry Status and Trend
Table 155. Meningococcal Vaccine Key Raw Materials and Upstream Suppliers
Table 156. Meningococcal Vaccine Clients Status and Trend
Table 157. Meningococcal Vaccine Typical Clients
Table 158. Meningococcal Vaccine Distributors
Table 159. Meningococcal Vaccine Market Trends
Table 160. Meningococcal Vaccine Market Drivers
Table 161. Meningococcal Vaccine Market Challenges
Table 162. Meningococcal Vaccine Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
Table 166. QYR Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Meningococcal Vaccine Product Picture
Figure 2. Global Meningococcal Vaccine Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Meningococcal Vaccine Sales Market Share by Type in 2024 & 2031
Figure 4. Meningtits A Product Picture
Figure 5. Polysaccharide Meningtitis AC Product Picture
Figure 6. Meningitis ACYW Product Picture
Figure 7. Global Meningococcal Vaccine Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Meningococcal Vaccine Sales Market Share by Application in 2024 & 2031
Figure 9. 6 Months-15Year
Figure 10. over 3 Year
Figure 11. over 2 Year
Figure 12. over 3 Months
Figure 13. Meningococcal Vaccine Report Years Considered
Figure 14. Global Meningococcal Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Meningococcal Vaccine Market Size 2020-2031 (US$ Million)
Figure 16. Global Meningococcal Vaccine Sales 2020-2031 (10K Pcs)
Figure 17. Global Meningococcal Vaccine Sales Market Share Forecast by Region (2020-2031)
Figure 18. Global Meningococcal Vaccine Revenue Market Share by Region (2020-2031)
Figure 19. Global Meningococcal Vaccine Sales Market Share Forecast by Type (2020-2031)
Figure 20. Global Meningococcal Vaccine Revenue Market Share Forecast by Type (2020-2031)
Figure 21. Meningococcal Vaccine Average Selling Price (ASP) by Type (2020-2025) & (USD/Pcs)
Figure 22. Global Meningococcal Vaccine Sales Market Share Forecast by Application (2020-2031)
Figure 23. Global Meningococcal Vaccine Revenue Market Share Forecast by Application (2020-2031)
Figure 24. Meningococcal Vaccine Average Selling Price (ASP) by Application (2020-2025) & (USD/Pcs)
Figure 25. Meningtits A of Meningococcal Vaccine Revenue Market Share by Application, 2024 VS 2031
Figure 26. Polysaccharide Meningtitis AC of Meningococcal Vaccine Revenue Market Share by Application, 2024 VS 2031
Figure 27. Meningitis ACYW of Meningococcal Vaccine Revenue Market Share by Application, 2024 VS 2031
Figure 28. Global Meningococcal Vaccine Sales Share by Manufacturer in 2024
Figure 29. Meningococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 30. Meningtits A Market Sales Proportion by Manufacturer in 2024
Figure 31. Polysaccharide Meningtitis AC Market Sales Proportion by Manufacturer in 2024
Figure 32. Meningitis ACYW Market Sales Proportion by Manufacturer in 2024
Figure 33. North America Meningococcal Vaccine Revenue 2020-2031 (US$ Million)
Figure 34. North America Meningococcal Vaccine Sales Market Share by Type (2020-2025)
Figure 35. North America Meningococcal Vaccine Sales Market Share by Application (2020-2025)
Figure 36. Asia-Pacific Meningococcal Vaccine Revenue 2020-2031 (US$ Million)
Figure 37. Asia-Pacific Meningococcal Vaccine Sales Market Share by Region (2020-2031)
Figure 38. Asia-Pacific Meningococcal Vaccine Revenue Market Share by Region (2020-2031)
Figure 39. Asia-Pacific Meningococcal Vaccine Sales Market Share by Type (2020-2025)
Figure 40. Asia-Pacific Meningococcal Vaccine Sales Market Share by Application (2020-2025)
Figure 41. Europe Meningococcal Vaccine Revenue Growth Rate 2020-2031 (US$ Million)
Figure 42. Europe Meningococcal Vaccine Sales Market Share by Country (2020-2031)
Figure 43. Europe Meningococcal Vaccine Revenue Market Share by Country (2020-2031)
Figure 44. Europe Meningococcal Vaccine Sales Market Share by Type (2020-2025)
Figure 45. Europe Meningococcal Vaccine Sales Market Share by Application (2020-2025)
Figure 46. Latin America Meningococcal Vaccine Revenue Growth Rate 2020-2031 (US$ Million)
Figure 47. Latin America Meningococcal Vaccine Sales Market Share by Country (2020-2031)
Figure 48. Latin America Meningococcal Vaccine Revenue Market Share by Country (2020-2025)
Figure 49. Latin America Meningococcal Vaccine Sales Market Share by Type (2020-2025)
Figure 50. Latin America Meningococcal Vaccine Sales Market Share by Application (2020-2025)
Figure 51. Middle East and Africa Meningococcal Vaccine Revenue Growth Rate 2020-2031 (US$ Million)
Figure 52. Middle East and Africa Meningococcal Vaccine Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Meningococcal Vaccine Revenue Market Share by Country (2020-2031)
Figure 54. Middle East and Africa Meningococcal Vaccine Sales Market Share by Type (2020-2025)
Figure 55. Middle East and Africa Meningococcal Vaccine Sales Market Share by Application (2020-2025)
Figure 56. Meningococcal Vaccine Supply Chain (Upstream and Downstream Market)
Figure 57. Global Production Market Share of Meningococcal Vaccine Raw Materials by Region in 2024
Figure 58. Meningococcal Vaccine Distribution Channels
Figure 59. Global Meningococcal Vaccine Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 60. Global Meningococcal Vaccine Percentage 2020-2031: Online Sales VS Offline Sales
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Meningococcal Vaccine Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Meningococcal Vaccine Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Meningococcal Vaccine Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Meningococcal Vaccine Sales by Region (2020-2025) & (10K Pcs)
Table 5. Global Meningococcal Vaccine Sales Forecast by Region (2026-2031) & (10K Pcs)
Table 6. Global Meningococcal Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 7. Global Meningococcal Vaccine Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 8. Global Meningococcal Vaccine Sales Volume by Type (2020-2025) & (10K Pcs)
Table 9. Global Meningococcal Vaccine Sales Volume by Type (2026-2031) & (10K Pcs)
Table 10. Global Meningococcal Vaccine Revenue by Type (2020-2025) & (US$ Million)
Table 11. Global Meningococcal Vaccine Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 12. Global Meningococcal Vaccine Sales Volume by Application (2020-2025) & (10K Pcs)
Table 13. Global Meningococcal Vaccine Sales Volume by Application (2026-2031) & (10K Pcs)
Table 14. Global Meningococcal Vaccine Revenue by Application (2020-2025) & (US$ Million)
Table 15. Global Meningococcal Vaccine Revenue by Application (2026-2031) & (US$ Million)
Table 16. Global Meningococcal Vaccine Sales by Manufacturer (2020-2025) & (10K Pcs)
Table 17. Global Meningococcal Vaccine Sales Share by Manufacturer (2020-2025)
Table 18. Meningococcal Vaccine Revenue by Manufacturer (2020-2025) & (US$ Million)
Table 19. Meningococcal Vaccine Revenue Share by Manufacturer (2020-2025)
Table 20. Key Manufacturers Meningococcal Vaccine Price (2020-2025) & (USD/Pcs)
Table 21. Ranking of Global Top Meningococcal Vaccine Manufacturers by Revenue (US$ Million) in 2024
Table 22. Global Meningococcal Vaccine Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 23. Global Meningococcal Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Meningococcal Vaccine as of 2024)
Table 24. Meningococcal Vaccine Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Date of International Manufacturers Enter into Meningococcal Vaccine Market
Table 26. Manufacturers Meningococcal Vaccine Product Type and Application
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Novartis Company Information
Table 29. Novartis Description and Business Overview
Table 30. Novartis Meningococcal Vaccine Product
Table 31. Novartis Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 32. Novartis Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 33. Novartis Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 34. Novartis Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 35. Novartis Recent Developments
Table 36. GSK Company Information
Table 37. GSK Description and Business Overview
Table 38. GSK Meningococcal Vaccine Product
Table 39. GSK Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 40. GSK Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 41. GSK Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 42. GSK Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 43. GSK Recent Developments
Table 44. Merck Company Information
Table 45. Merck Description and Business Overview
Table 46. Merck Meningococcal Vaccine Product
Table 47. Merck Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 48. Merck Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 49. Merck Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 50. Merck Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 51. Merck Recent Developments
Table 52. CSL Company Information
Table 53. CSL Description and Business Overview
Table 54. CSL Meningococcal Vaccine Product
Table 55. CSL Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 56. CSL Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 57. CSL Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 58. CSL Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 59. CSL Recent Developments
Table 60. Baxter Company Information
Table 61. Baxter Description and Business Overview
Table 62. Baxter Meningococcal Vaccine Product
Table 63. Baxter Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 64. Baxter Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 65. Baxter Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 66. Baxter Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 67. Baxter Recent Developments
Table 68. JN International Medical Corporation Company Information
Table 69. JN International Medical Corporation Description and Business Overview
Table 70. JN International Medical Corporation Meningococcal Vaccine Product
Table 71. JN International Medical Corporation Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 72. JN International Medical Corporation Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 73. JN International Medical Corporation Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 74. JN International Medical Corporation Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 75. JN International Medical Corporation Recent Developments
Table 76. Serum Institute of India Company Information
Table 77. Serum Institute of India Description and Business Overview
Table 78. Serum Institute of India Meningococcal Vaccine Product
Table 79. Serum Institute of India Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 80. Serum Institute of India Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 81. Serum Institute of India Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 82. Serum Institute of India Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 83. Serum Institute of India Recent Developments
Table 84. Bio-Med Company Information
Table 85. Bio-Med Description and Business Overview
Table 86. Bio-Med Meningococcal Vaccine Product
Table 87. Bio-Med Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 88. Bio-Med Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 89. Bio-Med Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 90. Bio-Med Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 91. Bio-Med Recent Developments
Table 92. China National Biotec Group Company Information
Table 93. China National Biotec Group Description and Business Overview
Table 94. China National Biotec Group Meningococcal Vaccine Product
Table 95. China National Biotec Group Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 96. China National Biotec Group Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 97. China National Biotec Group Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 98. China National Biotec Group Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 99. China National Biotec Group Recent Developments
Table 100. Hualan Bio Company Information
Table 101. Hualan Bio Description and Business Overview
Table 102. Hualan Bio Meningococcal Vaccine Product
Table 103. Hualan Bio Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 104. Hualan Bio Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 105. Hualan Bio Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 106. Hualan Bio Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 107. Hualan Bio Recent Developments
Table 108. Walvax Company Information
Table 109. Walvax Description and Business Overview
Table 110. Walvax Meningococcal Vaccine Product
Table 111. Walvax Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 112. Walvax Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 113. Walvax Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 114. Walvax Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 115. Walvax Recent Developments
Table 116. Zhifei Company Information
Table 117. Zhifei Description and Business Overview
Table 118. Zhifei Meningococcal Vaccine Product
Table 119. Zhifei Meningococcal Vaccine Sales (10K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 120. Zhifei Sales Proportion of Meningococcal Vaccine by Product in 2024
Table 121. Zhifei Sales Proportion of Meningococcal Vaccine by Application in 2024
Table 122. Zhifei Sales Proportion of Meningococcal Vaccine by Geographic Area in 2024
Table 123. Zhifei Recent Developments
Table 124. North America Meningococcal Vaccine Sales by Country (2020-2025) & (10K Pcs)
Table 125. North America Meningococcal Vaccine Sales by Country (2026-2031) & (10K Pcs)
Table 126. North America Meningococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 127. North America Meningococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 128. North America Meningococcal Vaccine Sales by Type (2020-2025) & (10K Pcs)
Table 129. North America Meningococcal Vaccine Sales by Application (2020-2025) & (10K Pcs)
Table 130. Asia-Pacific Meningococcal Vaccine Sales by Region (2020-2025) & (10K Pcs)
Table 131. Asia-Pacific Meningococcal Vaccine Sales by Region (2026-2031) & (10K Pcs)
Table 132. Asia-Pacific Meningococcal Vaccine Revenue by Region (2020-2025) & (US$ Million)
Table 133. Asia-Pacific Meningococcal Vaccine Revenue by Region (2026-2031) & (US$ Million)
Table 134. Asia-Pacific Meningococcal Vaccine Sales by Type (2020-2025) & (10K Pcs)
Table 135. Asia-Pacific Meningococcal Vaccine Sales by Application (2020-2025) & (10K Pcs)
Table 136. Europe Meningococcal Vaccine Sales by Country (2020-2025) & (10K Pcs)
Table 137. Europe Meningococcal Vaccine Sales by Country (2026-2031) & (10K Pcs)
Table 138. Europe Meningococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 139. Europe Meningococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 140. Europe Meningococcal Vaccine Sales by Type (2020-2025) & (10K Pcs)
Table 141. Europe Meningococcal Vaccine Sales by Application (2020-2025) & (10K Pcs)
Table 142. Latin America Meningococcal Vaccine Sales by Country (2020-2025) & (10K Pcs)
Table 143. Latin America Meningococcal Vaccine Sales by Country (2026-2031) & (10K Pcs)
Table 144. Latin America Meningococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 145. Latin America Meningococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 146. Latin America Meningococcal Vaccine Sales by Type (2020-2025) & (10K Pcs)
Table 147. Latin America Meningococcal Vaccine Sales by Application (2020-2025) & (10K Pcs)
Table 148. Middle East and Africa Meningococcal Vaccine Sales by Country (2020-2025) & (10K Pcs)
Table 149. Middle East and Africa Meningococcal Vaccine Sales by Country (2026-2031) & (10K Pcs)
Table 150. Middle East and Africa Meningococcal Vaccine Revenue by Country (2020-2025) & (US$ Million)
Table 151. Middle East and Africa Meningococcal Vaccine Revenue by Country (2026-2031) & (US$ Million)
Table 152. Middle East and Africa Meningococcal Vaccine Sales by Type (2020-2025) & (10K Pcs)
Table 153. Middle East and Africa Meningococcal Vaccine Sales by Application (2020-2025) & (10K Pcs)
Table 154. Meningococcal Vaccine Key Raw Materials, Industry Status and Trend
Table 155. Meningococcal Vaccine Key Raw Materials and Upstream Suppliers
Table 156. Meningococcal Vaccine Clients Status and Trend
Table 157. Meningococcal Vaccine Typical Clients
Table 158. Meningococcal Vaccine Distributors
Table 159. Meningococcal Vaccine Market Trends
Table 160. Meningococcal Vaccine Market Drivers
Table 161. Meningococcal Vaccine Market Challenges
Table 162. Meningococcal Vaccine Market Restraints
Table 163. Research Programs/Design for This Report
Table 164. Key Data Information from Secondary Sources
Table 165. Key Data Information from Primary Sources
Table 166. QYR Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Meningococcal Vaccine Product Picture
Figure 2. Global Meningococcal Vaccine Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Meningococcal Vaccine Sales Market Share by Type in 2024 & 2031
Figure 4. Meningtits A Product Picture
Figure 5. Polysaccharide Meningtitis AC Product Picture
Figure 6. Meningitis ACYW Product Picture
Figure 7. Global Meningococcal Vaccine Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 8. Global Meningococcal Vaccine Sales Market Share by Application in 2024 & 2031
Figure 9. 6 Months-15Year
Figure 10. over 3 Year
Figure 11. over 2 Year
Figure 12. over 3 Months
Figure 13. Meningococcal Vaccine Report Years Considered
Figure 14. Global Meningococcal Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Meningococcal Vaccine Market Size 2020-2031 (US$ Million)
Figure 16. Global Meningococcal Vaccine Sales 2020-2031 (10K Pcs)
Figure 17. Global Meningococcal Vaccine Sales Market Share Forecast by Region (2020-2031)
Figure 18. Global Meningococcal Vaccine Revenue Market Share by Region (2020-2031)
Figure 19. Global Meningococcal Vaccine Sales Market Share Forecast by Type (2020-2031)
Figure 20. Global Meningococcal Vaccine Revenue Market Share Forecast by Type (2020-2031)
Figure 21. Meningococcal Vaccine Average Selling Price (ASP) by Type (2020-2025) & (USD/Pcs)
Figure 22. Global Meningococcal Vaccine Sales Market Share Forecast by Application (2020-2031)
Figure 23. Global Meningococcal Vaccine Revenue Market Share Forecast by Application (2020-2031)
Figure 24. Meningococcal Vaccine Average Selling Price (ASP) by Application (2020-2025) & (USD/Pcs)
Figure 25. Meningtits A of Meningococcal Vaccine Revenue Market Share by Application, 2024 VS 2031
Figure 26. Polysaccharide Meningtitis AC of Meningococcal Vaccine Revenue Market Share by Application, 2024 VS 2031
Figure 27. Meningitis ACYW of Meningococcal Vaccine Revenue Market Share by Application, 2024 VS 2031
Figure 28. Global Meningococcal Vaccine Sales Share by Manufacturer in 2024
Figure 29. Meningococcal Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 30. Meningtits A Market Sales Proportion by Manufacturer in 2024
Figure 31. Polysaccharide Meningtitis AC Market Sales Proportion by Manufacturer in 2024
Figure 32. Meningitis ACYW Market Sales Proportion by Manufacturer in 2024
Figure 33. North America Meningococcal Vaccine Revenue 2020-2031 (US$ Million)
Figure 34. North America Meningococcal Vaccine Sales Market Share by Type (2020-2025)
Figure 35. North America Meningococcal Vaccine Sales Market Share by Application (2020-2025)
Figure 36. Asia-Pacific Meningococcal Vaccine Revenue 2020-2031 (US$ Million)
Figure 37. Asia-Pacific Meningococcal Vaccine Sales Market Share by Region (2020-2031)
Figure 38. Asia-Pacific Meningococcal Vaccine Revenue Market Share by Region (2020-2031)
Figure 39. Asia-Pacific Meningococcal Vaccine Sales Market Share by Type (2020-2025)
Figure 40. Asia-Pacific Meningococcal Vaccine Sales Market Share by Application (2020-2025)
Figure 41. Europe Meningococcal Vaccine Revenue Growth Rate 2020-2031 (US$ Million)
Figure 42. Europe Meningococcal Vaccine Sales Market Share by Country (2020-2031)
Figure 43. Europe Meningococcal Vaccine Revenue Market Share by Country (2020-2031)
Figure 44. Europe Meningococcal Vaccine Sales Market Share by Type (2020-2025)
Figure 45. Europe Meningococcal Vaccine Sales Market Share by Application (2020-2025)
Figure 46. Latin America Meningococcal Vaccine Revenue Growth Rate 2020-2031 (US$ Million)
Figure 47. Latin America Meningococcal Vaccine Sales Market Share by Country (2020-2031)
Figure 48. Latin America Meningococcal Vaccine Revenue Market Share by Country (2020-2025)
Figure 49. Latin America Meningococcal Vaccine Sales Market Share by Type (2020-2025)
Figure 50. Latin America Meningococcal Vaccine Sales Market Share by Application (2020-2025)
Figure 51. Middle East and Africa Meningococcal Vaccine Revenue Growth Rate 2020-2031 (US$ Million)
Figure 52. Middle East and Africa Meningococcal Vaccine Sales Market Share by Country (2020-2031)
Figure 53. Middle East and Africa Meningococcal Vaccine Revenue Market Share by Country (2020-2031)
Figure 54. Middle East and Africa Meningococcal Vaccine Sales Market Share by Type (2020-2025)
Figure 55. Middle East and Africa Meningococcal Vaccine Sales Market Share by Application (2020-2025)
Figure 56. Meningococcal Vaccine Supply Chain (Upstream and Downstream Market)
Figure 57. Global Production Market Share of Meningococcal Vaccine Raw Materials by Region in 2024
Figure 58. Meningococcal Vaccine Distribution Channels
Figure 59. Global Meningococcal Vaccine Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 60. Global Meningococcal Vaccine Percentage 2020-2031: Online Sales VS Offline Sales
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Trichosanthes Kirilowii Extract Market Research Report 2026
Feb 24, 26
Global Glass Lined Containers Market Research Report 2026
Feb 24, 26
Global Open End Wrenches Market Research Report 2026
Feb 24, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232